why choose us

Course: Incorporating HER2-Low and HER2-Ultralow in Optimizing Treatment of mBC

CME Credits: 0.75

Released: 2026-06-24

The landscape regarding diagnosis and treatment of human epidermal growth factor receptor 2 (HER2)-low and -ultralow mBC continues to evolve. This case-based discussion will include perspectives from medical oncology, pathology, and patients covering topics from testing and diagnosis to treatment. Our expert faculty will discuss clinical trial data of new and emerging antibody-drug conjugates (ADCs), updated recommendations for optimal treatment selection, and how to manage ADC-specific adverse events (AEs). Clinical decision-making will be highlighted through a patient perspective, supported by evidence-based strategies that assess HER2-low and HER2-ultralow expression profiles.


Upon completion of this activity, participants should be better able to:


View Full Course